EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL. (June 2017)

• Record Type: Journal Article
• Authors: Pettitt, A.R.; Kalakonda, N.; Polydoros, F.; Bickerstaff, M.; Menon, G.; Coupland, S.E.; Oates, M.; Lin, K.; Pocock, C.; Jenkins, S.; Schuh, A.; Wandroo, F.; Rassam, S.; Duncombe, A.S.; Jenner, M.; Cervi, P.; Paneesha, S.; Aldouri, M.; Fox, C.P.; Knechtli, C.; Hamblin, M.; Turner, D.; Hillmen, P.
• Is Part Of: Hematological oncology. Volume 35(2017)Supplement 2
• Page Start: 88
• Page End: 89
• Publication Date: 2017-06
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2437_77
• Languages: English
• ISSNs: 0278-0232